Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Portfolio Pulse from
Kadimastem and iTolerance have successfully completed a pre-IND meeting with the FDA for their Type 1 Diabetes treatment, iTOL-102, which could potentially cure diabetes without chronic immune suppression.
February 25, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NLS Pharmaceutics Ltd. is involved in the collaborative development of iTOL-102, a promising Type 1 Diabetes treatment, which has successfully completed a pre-IND meeting with the FDA.
The successful pre-IND meeting with the FDA is a positive regulatory step for NLS Pharmaceutics Ltd., indicating progress in the development of iTOL-102. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 50